
Rapid tech advancements and soaring demand are positioning the biotech sector for rapid growth in the near term. Advances in genetic engineering, novel medicines, and greater investment in biotech companies and pharmaceutical alliances boost the sector.
So, quality biotech stock Acorda Therapeutics, Inc. (ACOR) could be worth buying. However, Moderna, Inc. (MRNA) is best avoided, considering its weak fundamentals.